Navigation Links
Vasogen Announces Second Quarter 2009 Results
Date:7/14/2009

MISSISSAUGA, ON, July 14 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN; TSX:VAS) today reported the results of operations for the three and six months ended May 31, 2009. All dollar amounts referenced herein are in Canadian dollars unless otherwise noted.

At May 31, 2009, our cash and cash equivalents totaled $5.8 million, compared with $7.3 million at February 28, 2009. Our net cash used in operating activities for the three and six months ended May 31, 2009, was $1.4 million and $3.2 million, respectively, compared with $7.6 million and $11.0 million for the same periods in 2008. The $1.4 million of net cash used in operating activities for the three months ended May 31, 2009 included the payment of $0.6 million in accounts payable and accrued liabilities that were outstanding as at February 28, 2009 and $0.4 million in one-time payments for our insurance programs which should provide the necessary coverage in the event that our strategic review process results in our Company being sold, merged, acquired, dissolved, or liquidated.

The net loss for the second quarter of 2009 was $1.4 million, or $0.06 per common share, compared with a net loss of $7.4 million, or $0.33 per common share for the same period in 2008. The $1.4 million loss for the three months ended May 31, 2009 included a charge for restructuring costs of $0.5 million, professional fees, mainly related to our ongoing strategic review, of $0.3 million, the amortization of insurance that has been previously paid in the amount of $0.1 million, and a non-cash stock compensation expense of $0.1 million during the second quarter of 2009.

We incurred a net loss for the six months ended May 31, 2009 of $3.3 million, or $0.15 per common share, compared with a net loss of $12.7 million, or $0.57 per common share for the same period in 2008. The loss for the three and six months end
'/>"/>

SOURCE Vasogen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)..., SHANGHAI, Dec. 1 /PRNewswire-Asia/ -- Shang...ngPharma, a leading China-based Contract Research,... of the 2009 Deloitte,Technology Fast 50 China, ra...tech companies in China. The award is a testament ...owth from 2006 to 2008. , The results of ...
(Date:12/1/2009)..., SAN FRANCISCO, Dec. 1 The Burril... half the value it lost in October. The Select,s g...lent month for the general markets with the Dow up...e. The gains held firm in the final two trading da...ggish Thanksgiving holiday shopping and Dubai,s re...
(Date:12/1/2009)... Congruent Software agrees to migra...project accounting clients) to Synergy Business So... Seattle, WA (PRWEB) December 1, 2009...has acquired the Microsoft Dynamics SL practice of...ology provider. The move was necessary due to a ch...
(Date:12/1/2009)... , HUNTINGTON BEACH, California and AMSTER...eader in molecular cancer diagnostics, announced t...re administrator, has established,coding guideline... Agendia,s,FDA-cleared breast cancer recurrence te.... , Patients across the United States can...
Breaking Biology Technology:Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 2Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies 3Biotech Gets Back on Track in November 2Biotech Gets Back on Track in November 3Biotech Gets Back on Track in November 4Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 2Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc. 3Medicare Administrator Establishes Reimbursement Coding Policy for Agendia's Breast Cancer Recurrence Test MammaPrint(R) 2
.... 29 Allos,Therapeutics, Inc. (Nasdaq: ALTH ), a...ent and commercialization of small molecule therap...d that members of the Company,s,senior management ...ill,Lynch Global Pharmaceutical, Biotechnology and...any,s presentation will take place at 11:00 a.m. (...
...swire/ - Viventia Biotech Inc., a privately held,b...novel antibody,therapeutics focused on cancer, ann...natives to further advance and realize value from ...dy discovery platform and its,antibody manufacturi...al,strategic opportunities including, but not limi...
...to Canadian HAI Market; Market Expenditures for MR...llion by 2012, SUNNYVALE, Calif., Jan. 29 Cephei...a has issued a medical device,license for the Xper...llin,Resistant Staphylococcus aureus (MRSA) on nas...est results are available in approximately 70 minu...
Other Biology Technology:Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference 2Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data 2Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data 3Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data 4Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data 5Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data 6Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System 2Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System 3Cepheid Receives Health Canada Medical Device License for Xpert MRSA(TM) Test and GeneXpert(R) System 4
(Date:12/1/2009)...Ben-Ari, winner of the 2009 Inserm Grand Prix., ...mitment to paying tribute to outstanding,work per...ouring talents, Inserm intends to,demonstrate the...day,s biological, medical and,health research, an...who carry out and,drive this research each day. T...
(Date:12/1/2009)...LE, Fla. Hit-and-run attacks by sharks can be sol...its by the unique chomp they put on their victims,...nd shark expert. , In a method analogous to anal...tifications by precisely comparing shark bites to ... George Burgess, director of the International Sha...
(Date:12/1/2009)...d first, a Monash University-led international res...t the output of the next generation of solar cells...ation with colleagues from the universities of Wol...ye-sensitised solar cells with a three-fold increa...reviously reported tandem dye-sensitised solar cel...
Breaking Biology News(10 mins):Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 3New forensic technique gives clues about sharks from bite damage 2New forensic technique gives clues about sharks from bite damage 3Innovation puts next-generation solar cells on the horizon 2Researchers estimate risk of transmission of Huntingtons disease to offspring among male carriers 48309 1Researchers estimate risk of transmission of Huntingtons disease to offspring among male carriers 48309 2VisionDirect com Offers Contact Lens Customers a New Way to Pay 48307 1VisionDirect com Offers Contact Lens Customers a New Way to Pay 48307 2VisionDirect com Offers Contact Lens Customers a New Way to Pay 48307 3Accumetrics Inc Announces Distribution Channels in Israel and Cyprus 48302 1Accumetrics Inc Announces Distribution Channels in Israel and Cyprus 48302 2
...w research shows that we should be looking to the ...ould have its most perilous impact on life on Eart...borough have published research findings in the pr...global warming actually changes the molecular stru...s more than twice the amount of carbon than does t...
...new study by Narendra et al. suggests that Parkin,...ne Park2, prompts neuronal survival by clearing th... an exciting new discovery that links the fields o...f Parkinson,s disease (PD)," writes Heidi McBride ... work significantly increases our understanding of...
...lacksburg, Va. An international consortium of res...e of the domesticated turkey, Meleagris gallopavo....che GS-FLX sequencing platform and the recently la... and reagents. , The new upgrade to the Roche GS... individual sequencing reads to be generated for e...
Other Biology News:Global warming is changing organic matter in soil 2Research consortium to sequence turkey genome 2Research consortium to sequence turkey genome 3Research consortium to sequence turkey genome 4
...ombinant RNasin Ribonuclease Inhibitors have broad...he inhibition of eukaryotic RNases of the neutral ...effect by noncovalently binding to RNases in a 1:1...onuclease Inhibitor to RNase (e.g., RNase A) is ap...
Biolase Core Kit from Bioline
Goat Anti-Rat UGT1A7 (E-15) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
CnAOSMC (Cn354-05) from European Collection of Cell Cultures (ECACC)
Biology Products: